glp 1 meds and alzheimer's Details of failed studies cast pall on Novo Nordisk's GLP-1 as treatment GLP-1 drugs failed to slow

Another potential question that clinical trials will need to assess is whether GLP-1 drugs are actually safe to take for people without obesity or diabetes, as the weight loss these drugs induce could be a damaging side effect

(Lond.) 588, 32953305

Weight loss induces changes in vitamin D status in women with obesity but not in men: a randomized clinical trial

Emerging evidence also suggests GLP-1s increase cerebral blood flow through arteriolar vasodilation and may promote angiogenesis, helping restore metabolic support in vulnerable brain regions [13]

Pharmacological upregulation of Hrd1 expression or activity may accelerate the clearance of misfolded proteins, thereby reducing ER stress and preventing cardiomyocyte apoptosis, an approach particularly relevant in diabetic cardiomyopathy